GoodRx vs Waystar
Waystar reported revenue of $1.1 billion in fiscal 2025, 1.4 times GoodRx's $797 million in fiscal 2025. GoodRx's revenue grew 0.6% in its latest year, and Waystar's grew 16.5%. GoodRx had an operating margin of 11.0%, against 22.7% at Waystar. Free cash flow was $164 million at GoodRx and $283 million at Waystar.
Side by side
| GoodRx | Waystar | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $797M | $1.1B |
| Revenue growth | 0.6% | 16.5% |
| Revenue growth a year, last 5 years | 7.7% | — |
| Gross margin | — | — |
| Operating margin | 11.0% | 22.7% |
| Net margin | 3.8% | 10.2% |
| Free cash flow | $164M | $283M |
| Free cash flow margin | 20.6% | 25.8% |
| Return on capital | 5.8% | 3.5% |
| Net debt to EBITDA | 1.4x | 3.6x |
| Dividends and buybacks | $216M | $0M |
| Change in diluted share count | −9.0% | 23.3% |
| Last close | $3.02 | $27.09 |
| P/E at the last close | 75.5× | 39.3× |
| Insider trades, last 12 months | sold $9.7 million | bought $189,000, sold $10.5 million |
| Piotroski F-score | 6 of 8 | 5 of 8 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
GoodRxWaystar
Operating margin
Percent of revenue
GoodRxWaystar
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
GoodRxWaystar